ROS1 and cholangiocarcinoma: Four CCA cell lines were employed to determine the sensitivity to crizotinib—a cMet, ALK, and ROS1 inhibitor, ceritinib—an ALK inhibitor, and capmatinib (INCB28060)—a cMet-specific inhibitor.